XWELL, Inc. (XWEL) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2025. XWELL, Inc. is a global wellness organization operating three reportable segments: XpresSpa (airport spa services), XpresTest (bio-surveillance and public health support), and Naples Wax Center (hair removal and skincare). The company also operates HyperPointe, a B2B marketing subsidiary. As of June 30, 2025, there were 5,756,703 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|
| Total Revenue | $7.69 million | $14.71 million | $18.01 million |
| Gross Profit | $1.78 million (23.1% margin) | $3.09 million (21.0% margin) | $5.74 million (31.9% margin) |
| Operating Loss | $(2.69 million) | $(5.85 million) | $(4.27 million) |
| Net Loss (Attributable to XWELL) | $(2.27 million) | $(6.99 million) | $(4.51 million) |
| Cash & Equivalents | $5.26 million | $5.26 million | $4.55 million (Dec 31, 2024) |
| Marketable Securities | $2.89 million | $2.89 million | $7.25 million (Dec 31, 2024) |
| Total Current Liabilities | $9.48 million | $9.48 million | $9.22 million (Dec 31, 2024) |
| Working Capital | $2.36 million | $2.36 million | $6.11 million (Dec 31, 2024) |
Debt & Liquidity: The company has no traditional senior debt but carries significant operating lease liabilities ($9.99 million total). A new Series G Convertible Preferred Stock was issued in January 2025 with a liquidation preference of $3.6 million. The company reported a net cash outflow from operating activities of $6.56 million for the six months ended June 30, 2025.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 17% quarter-over-quarter and 18% year-over-year (YTD). This was primarily driven by a reduction in XpresTest revenue due to the conclusion of specific CDC surge billing periods and a decrease in Priority Pass revenue for XpresSpa compared to the prior year.
- Margin Compression: Gross margin declined from 31.9% in YTD 2024 to 21.0% in YTD 2025. While cost of sales decreased in absolute dollars, the reduction was outpaced by the revenue decline. Higher costs of supplies for anticipated store openings also impacted margins.
- Non-Operating Volatility: The YTD 2025 net loss was significantly impacted by a $3.44 million loss on the issuance of Series G Preferred Stock. Conversely, the company recognized a $3.22 million gain from the change in fair value of warrant liabilities and a $0.28 million gain from derivative liabilities, largely due to a decrease in the company's stock price post-issuance.
- Foreign Exchange: A foreign exchange loss of $1.0 million (YTD 2025) compared to $0.14 million (YTD 2024) was recorded, primarily due to currency fluctuations in Turkey affecting lease liability remeasurement.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for at least one year from the issuance date. The company has insufficient liquidity to fund future operations without raising additional capital or reducing operations further.
- Capital Raising: The company is actively exploring financing options. In January 2025, it completed a private placement raising $4.0 million gross ($3.75 million net) via Series G Preferred Stock and warrants.
- Nasdaq Compliance: The company previously failed to meet the $1.00 minimum bid price requirement in May 2025 but regained compliance in August 2025.
- Internal Control Weaknesses: The company identified material weaknesses in internal controls over financial reporting, specifically regarding lease accounting (ASC 842), revenue processes, and monitoring controls over foreign subsidiaries and IT vendors.
- Legal Proceedings: An arbitration proceeding is ongoing with Cordial Endeavor Concessions regarding XpresSpa locations in Atlanta, with a hearing scheduled for March 2026.
Investor Verification Checklist
- Liquidity Runway: Verify the company's specific plan and timeline for raising additional capital to address the "substantial doubt" going concern warning.
- Preferred Stock Terms: Review the redemption schedule and dividend obligations for the Series G Convertible Preferred Stock, which requires quarterly cash or share payments starting July 1, 2025.
- Revenue Sustainability: Assess the long-term viability of the XpresTest segment following the reduction in CDC-related surge revenue and the transition to the new three-year bio-surveillance contract.
- Internal Controls: Monitor the progress of the remediation plan for material weaknesses in financial reporting, particularly regarding lease and revenue accounting.
- Stock Price Volatility: Note the impact of stock price fluctuations on the fair value of warrant and derivative liabilities, which creates significant non-cash volatility in net income.